To The Moon

TRANSCENTA-B (06628) announced that it has entered into a strategic collaboration and a non-exclusive technology license agreement with EirGenix Inc. (TWSE: 6589), a global biopharmaceutical development and manufacturing company. Under the agreement, the Company will grant EirGenix a non-exclusive license to its Highly Integrated Continuous Bioprocessing (HiCB) platform, which encompasses high-yield continuous perfusion upstream processes and integrated hybrid continuous downstream purification technologies, along with complete process documentation, core process technology and expertise, and regulatory support services. The Company will receive a significant upfront payment and milestone payments, and is eligible to collect future royalties related to the commercial application of the licensed technology, fully reflecting both parties' shared expectation of creating long-term value through this collaboration. The HiCB platform is designed to achieve higher process efficiency, optimized process control, and product consistency, significantly reducing production costs compared to traditional fed-batch processes, ultimately helping more patients worldwide gain access to high-quality, affordable biologics. Based on this collaboration, EirGenix will adopt the Company's HiCB platform to support its biologic drug development projects and manufacturing operations; EirGenix plans to utilize the HiCB platform to serve CDMO clients seeking highly integrated continuous production solutions. "We are delighted to share our HiCB platform—a leading achievement in the field of highly integrated continuous bioprocessing—with like-minded partners to jointly drive the transformation of biologic drug production," said Dr. Qian Xueming, Chairman and Chief Executive Officer of the Company. "By enabling partners to apply the HiCB platform, we can collectively advance the affordability and global accessibility of innovative biologics. The revenue generated from this and future collaborations will be reinvested into strengthening the technology platform and advancing the R&D pipeline, dedicated to developing next-generation, best-in-class innovative therapies."